Klow

KLOW is a multi-peptide blend (80 mg total per vial). The dosing guidance below reflects common anecdotal protocols discussed for total daily blend amount (not per-peptide), typically run in cycles to support recovery-focused research.

Route & Frequency: Subcutaneous injection once daily is commonly used. Rotate injection sites (abdomen or other subcutaneous areas) to reduce irritation. Many protocols use a 5 days on / 2 days off schedule.

Reconstitution Target (80 mg vial): Reconstitute with 3–4 mL bacteriostatic water.
• 3.0 mL → ~26.7 mg/mL (more concentrated)
• 4.0 mL → 20 mg/mL (easier measuring, often preferred)
Conversion: 1 mL = 100 insulin units (U). Example: 10U = 0.10 mL.

*Loading phase example: Some protocols use 8 mg daily for the first 2 weeks (5 on / 2 off), then 4 mg daily for ~10 weeks using the same schedule.
Cycle duration: often 4–12 weeks, followed by 2–4 weeks off.

Precision Tip: If your calculated volume is very small (a few units or less), measurement accuracy becomes difficult. Many users choose 4.0 mL reconstitution for easier dosing and use 30U or 50U insulin syringes for better visibility.

Reconstitution Instructions:
• Clean vial tops with alcohol; use new sterile needles/syringes.
• Draw 3–4 mL bacteriostatic water and inject slowly down the vial wall to reduce foaming.
• Gently swirl/roll until fully dissolved (do not shake).
• Label with date and concentration; store refrigerated at 2–8 °C, protected from light.
• Use sterile technique for every draw; avoid contamination and unnecessary temperature cycling.

Sequence: Lys-Pro-Val

Molecular Formula: C₁₆H₃₀N₄O₄

Molecular Weight: 342.43 g mol^-1

PubChem CID: 125672

CAS Number: 67727-97-3

KLOW is a commercially available multi-peptide preparation labeled to combine four bioactive peptides: GHK-Cu, KPV, Thymosin β4 (often marketed as “TB-500”), and BPC-157. The scientific rationale typically presented for such blends is pathway coverage: each peptide has been studied (largely in preclinical or translational settings) in biological processes relevant to tissue repair and inflammatory signaling.

Importantly, much of the supporting evidence base pertains to the individual components, not to the specific four-peptide combination as a single, unified intervention. Any claim of “synergy” for a combined formulation should therefore be understood as a hypothesis unless directly demonstrated in controlled studies of the blend itself.

KLOW products are commonly labeled as a four-peptide blend with a total mass per vial reflecting a dominant GHK-Cu fraction plus smaller amounts of the remaining peptides. A frequently described label format is 50 mg GHK-Cu and 10 mg each of KPV, Thymosin β4 (“TB-500”), and BPC-157 (80 mg total). Actual composition and purity are supplier-dependent and should be verified via appropriate analytical documentation.

GHK-Cu (glycyl-L-histidyl-L-lysine–copper complex) is a naturally occurring human tripeptide that binds copper. In the scientific literature, GHK-Cu is frequently discussed in relation to extracellular matrix remodeling and skin/connective tissue repair signaling. Mechanistic and translational work often focuses on processes such as fibroblast-associated remodeling programs and tissue maintenance pathways, with a substantial portion of evidence originating from in vitro and translational models.

KPV (lysine–proline–valine) is commonly described as a short peptide motif derived from α-melanocyte-stimulating hormone (α-MSH). In research contexts, KPV is discussed for its anti-inflammatory and immune-modulating properties, including reported effects on inflammatory signaling pathways in experimental models. Interpretations are indication- and model-dependent, and the strength of evidence varies across systems.

Thymosin β4 (Tβ4) is a naturally occurring peptide best known for roles in actin dynamics and is widely discussed in relation to cell migration and wound repair biology. The strongest peer-reviewed mechanistic foundation is centered on Tβ4 itself; “TB-500” is frequently used in commercial contexts to refer to thymosin β4–related products.

BPC-157 is a 15–amino-acid peptide described as a stable gastric peptide with a broad preclinical research footprint. It is frequently studied in experimental contexts involving gastrointestinal mucosal protection and soft-tissue repair (e.g., muscle, tendon/ligament, and injury models). Reviews in recent years have emphasized that, despite extensive experimental work, robust human clinical evidence and safety data remain limited.

The rationale commonly used to justify a four-peptide blend is that each component is discussed in the literature within different, but overlapping, biological domains relevant to repair:

• Inflammation modulation: often attributed to α-MSH/KPV-related pathways and downstream signaling effects in experimental models.
• Remodeling programs: commonly associated with GHK-Cu in connective tissue/skin remodeling contexts.
• Cell migration and vascular response biology: frequently discussed for thymosin β4.
• Protective/repair effects in injury models: commonly discussed for BPC-157 in experimental systems.

This framework describes why the combination is proposed, but it does not establish additive or synergistic outcomes without direct studies on the combined formulation.

When describing KLOW in a scientific or educational manner, it is important to distinguish between (1) evidence on individual peptides and (2) evidence on the four-peptide blend itself. Across these components, a significant portion of the literature supporting repair or anti-inflammatory claims is preclinical (cell, animal, or translational models), and the strength of evidence varies by peptide and indication.

From a safety standpoint, preclinical tolerability reports do not automatically translate to established human safety—particularly when products are manufactured by different suppliers. For any research chemical product,identity and purity verification (e.g., appropriate analytical documentation) is a practical requirement for responsible use in laboratory contexts.

PubMed

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as 'in glass' studies, are conducted outside of living organisms. It's important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.